Introduction
Bietti’s crystalline dystrophy (BCD) is a rare, progressive chorioretinal degenerative disease that affects an estimated 1/67 000 individuals,1 predominantly those of East Asian descent.2 Age of onset is typically in the third decade of life, with clinical manifestations of decreased visual acuity, night blindness and visual field loss, which may be central or peripheral.1 3 Ocular exam may reveal crystalline deposits in the cornea and/or retina and sclerosis of choroidal vessels.1 3 In late-stage BCD, the intraretinal crystals disappear and give way to chorioretinal and retinal pigment epithelium (RPE) atrophy,4 and typically patients become legally blind by their 40–50s.1 BCD is inherited in an autosomal recessive pattern, and is due to mutations in the CYP4V2 gene.5 CYP4V2 is ubiquitously expressed in various tissues in the body, including the cornea and retina, and encodes for Cytochrome P450 4V2, an enzyme that is responsible for fatty acid metabolism.5 The hallmark crystalline inclusions of BCD have also been found outside of ocular tissue, including circulating lymphocytes and skin fibroblasts, suggesting that BCD is caused by a systemic dysfunction of lipid metabolism.3 6 However, there is extreme variability in BCD disease presentation. For example, progression may be asymmetric between the two eyes,7 and individuals with the same CYP4V2 mutation may present differently.8 9 As such, with its rarity, early asymptomatic stages, painless progression and high variability, BCD can be difficult to diagnose and study. Previous imaging modalities have been used to better characterise BCD; these include fundus photography, near infrared reflectance, fluorescein angiography, fundus autofluorescence (FAF) and others.
FAF is an efficient, non-invasive clinical imaging modality that reflects RPE lipofuscin distribution, using a known wave length excitation to detect lipofuscin emissions.10 Lipofuscin naturally accumulates in the RPE over time as a byproduct of the incomplete degradation of photoreceptor outer segments.11 12 Though retinal lipofuscin accumulation is a hallmark of normal ageing, abnormal patterns in lipofuscin density indicate certain retinal pathologies, and can be assessed accordingly with FAF. Previous clinical uses of FAF most prominently include age-related macular degeneration (AMD),13 14 which features abnormal lipofuscin accumulation,15 as well as many other macular dystrophies,16 including Stargardt disease10 and retinitis pigmentosa.17 There are various FAF wavelengths used, short-wavelength versus near infrared; there are also different FAF imaging systems, including fundus camera, confocal scanning laser ophthalmoscopes and ultrawidefield technologies.18 Regardless of their different imaging strategies, all FAF technologies are able to act as metabolic mapping tools of the retina and assess RPE overall health or dysfunctions.
Previous studies have reported FAF changes in patients with BCD. This study presents autofluorescence (AF) changes in BCD with particular focus on previously undescribed AF findings in choroidal vessels.